Abstract:In effort s to achieve minimal systemic toxicity and high tumor delivery efficiencies in cancer therapy, various nanomedicine formulations having stealth polymer coatings have been developed for minimizing immune cell uptake and off-target macrophage phagocyte system (MPS) organ accumulation. Despite an initial reduction in immune cell uptake, stealth nanoparticles still initiate an antibody immune response. This response acts on subsequent administrations in treatment regimens resulting in accelerated blood clearance of particles into MPS organs, particularly the liver, where they are retained for prolonged periods. Consequently, doses after the first administration in treatment regimens have diminished tumor accumulation and increased MPS toxicity. Here, we present a strategy reducing antibody responses to each dose in a treatment regimen by alternating between polyethylene-glycol and polymethyloxazoline polymers as the nanoparticle coating between administrations. In a weekly dosing regimen, we find that the first dose of particles having either coating display similar favorable pharmacokinetics and biodistributions, thus allowing the polymers to be used interchangeably. However, when maintaining the same coating in subsequent administrations, we find that particles are in circulation at the height of the antibody immune response resulting in 50-60% decreases of circulation half-lives and tumor accumulation along with 50% increases in liver accumulation. By alternating the polymers used in the nanoparticle coating between administrations, we find each dose maintains favorable in vivo behaviors at the height of the antibody immune response to the previous administration. Furthermore, our strategy increases the clearance of particles uptaken by macrophages and hepatocytes, resulting in marked decreases in hepatotoxicity. Statement of significance While nanoparticles with coatings consisting of stealth polymers can minimize immune cell uptake, they still initiate antibody immune responses leading to rapid blood clearance and MPS sequestration of subsequent administrations within a treatment regimen. We demonstrate that by alternating PEG and PMOZ polymer coatings between weekly administrations, the antibody immune response acting on each administration is minimal, and the favorable in vivo behaviors observed with the first administration is maintained in subsequent administrations. In this case, greater tumor accumulation is achieved while curtailing excessive MPS organ accumulation and toxicity throughout a nanomedicine treatment. We envision our strategy will benefit clinical trials where frequent administrations of therapeutics are required or in sequential deliveries of prognostic and therapeutic agents. (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Poly(HPMA-co-NIPAM) copolymer as an alternative to polyethylene glycol-based pharmacokinetic modulation of therapeutic proteins

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

Functionalisation of brush polyethylene glycol polymers with specific lipids extends their elimination half-life through association with natural lipid trafficking pathways

Therapeutic Protein PEPylation: the Helix of Nonfouling Synthetic Polypeptides Minimizes Antidrug Antibody Generation.

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Engineered polymeric excipients for enhancing the stability of protein biologics: Poly(N-isopropylacrylamide)-poly(ethylene glycol) (PNIPAM-PEG) block copolymers

Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

A hyperbranched amphiphilic acetal polymer for pH-sensitive drug delivery

Pyridine-2,6-dicarboxaldehyde-Enabled N-Terminal In Situ Growth of Polymer-Interferon Conjugates with Significantly Improved Pharmacokinetics and In Vivo Bioactivity

Polyethylene Glycol‐Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart

Impact of conjugation to different lipids on the lymphatic uptake and biodistribution of brush PEG polymers

In Situ Growth Of A Stoichiometric Peg-Like Conjugate At A Protein'S N-Terminus With Significantly Improved Pharmacokinetics

Pegloticase Co-Administered with High MW Polyethylene Glycol Effectively Reduces PEG-immunogenicity and Restores Prolonged Circulation in Mouse

Poly(ethyl Ethylene Phosphate): Overcoming the "polyethylene Glycol Dilemma" for Cancer Immunotherapy and Mrna Vaccination.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics

PEGylation of Guanidinium and Indole Bearing Poly(methacrylamide)s - Biocompatible Terpolymers for pDNA Delivery

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

Stable and Highly Efficient Antibody–Nanoparticles Conjugation

Poly(ethylene Glycol) Alternatives in Biomedical Applications

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Synthesis of amphiphilic alternating polyesters with oligo(ethylene glycol) side chains and potential use for sustained release drug delivery.